These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 28647378)

  • 1. Leishmaniasis drug discovery: recent progress and challenges in assay development.
    Zulfiqar B; Shelper TB; Avery VM
    Drug Discov Today; 2017 Oct; 22(10):1516-1531. PubMed ID: 28647378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease.
    Sharlow ER; Grögl M; Johnson J; Lazo JS
    Mol Interv; 2010 Apr; 10(2):72-5. PubMed ID: 20368366
    [No Abstract]   [Full Text] [Related]  

  • 3. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
    Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
    ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay development in leishmaniasis drug discovery: a comprehensive review.
    Zulfiqar B; Avery VM
    Expert Opin Drug Discov; 2022 Feb; 17(2):151-166. PubMed ID: 34818139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug search for leishmaniasis: a virtual screening approach by grid computing.
    Ochoa R; Watowich SJ; Flórez A; Mesa CV; Robledo SM; Muskus C
    J Comput Aided Mol Des; 2016 Jul; 30(7):541-52. PubMed ID: 27438595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
    Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.
    Aulner N; Danckaert A; Rouault-Hardoin E; Desrivot J; Helynck O; Commere PH; Munier-Lehmann H; Späth GF; Shorte SL; Milon G; Prina E
    PLoS Negl Trop Dis; 2013; 7(4):e2154. PubMed ID: 23593521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ex vivo multiparametric flow cytometry assay using human whole blood to simultaneously measure cytotoxicity and leishmanicidal activities.
    Ribeiro JM; Bandeira CC; de Faria BG; Alves MLR; Vieira FO; Giunchetti RC; Uzonna JE; Teixeira-Carvalho A; Peruhype-Magalhães V; Souza-Fagundes EM
    Exp Parasitol; 2020 Sep; 216():107940. PubMed ID: 32562606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs.
    Hefnawy A; Berg M; Dujardin JC; De Muylder G
    Trends Parasitol; 2017 Mar; 33(3):162-174. PubMed ID: 27993477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches to discover marine antileishmanial natural products.
    Tempone AG; Martins de Oliveira C; Berlinck RG
    Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmaniasis: diagnostic issues in Europe.
    Torpiano P; Pace D
    Expert Rev Anti Infect Ther; 2015; 13(9):1123-38. PubMed ID: 26211945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
    Borsari C; Jiménez-Antón MD; Eick J; Bifeld E; Torrado JJ; Olías-Molero AI; Corral MJ; Santarem N; Baptista C; Severi L; Gul S; Wolf M; Kuzikov M; Ellinger B; Reinshagen J; Witt G; Linciano P; Tait A; Costantino L; Luciani R; Tejera Nevado P; Zander-Dinse D; Franco CH; Ferrari S; Moraes CB; Cordeiro-da-Silva A; Ponterini G; Clos J; Alunda JM; Costi MP
    Eur J Med Chem; 2019 Dec; 183():111676. PubMed ID: 31542713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the drug screening approaches in leishmaniasis.
    Gopu B; Kour P; Pandian R; Singh K
    Int Immunopharmacol; 2023 Jan; 114():109591. PubMed ID: 36700771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of leishmaniasis: present challenges.
    Uliana SRB; Trinconi CT; Coelho AC
    Parasitology; 2018 Apr; 145(4):464-480. PubMed ID: 28103966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for sustainable approaches in antileishmanial drug discovery.
    Hendrickx S; Caljon G; Maes L
    Parasitol Res; 2019 Oct; 118(10):2743-2752. PubMed ID: 31473855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on small molecule strategies targeting leishmaniasis.
    Kapil S; Singh PK; Silakari O
    Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.
    Berry SL; Hameed H; Thomason A; Maciej-Hulme ML; Saif Abou-Akkada S; Horrocks P; Price HP
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006639. PubMed ID: 30001317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.